echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Concentrated procurement price wars one after another, pharmaceutical representatives still have three major outlets!

    Concentrated procurement price wars one after another, pharmaceutical representatives still have three major outlets!

    • Last Update: 2021-07-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News, March 1st.
    In early February, the "six provinces and two regions" (Sichuan Province, Shanxi Province, Inner Mongolia Autonomous Region, Liaoning Province, Jilin Province, Heilongjiang Province, Hainan Province, Tibet Autonomous Region) announced the results of the formal selection of volume procurement.
    The product fell sharply, basically close to the floor price
    .


    From the perspective of the “six provinces and two districts” of theprovincial union centralized procurement , except for Sichuan Province, the other regions are the second-class markets when drug marketers plan the national market.
    A single province pulls it out, and the centralized procurement report has a significant impact on manufacturers.
    The attraction is not as great as that of provinces like Henan, Shandong, Zhejiang, and Jiangsu
    .
    Thinking that Qinghai collected sourcing alone back then, there was an embarrassing scene where no manufacturer took care of it
    .
    "It doesn't matter if a province has a small amount.
    If several provinces with a small amount are tied to a province with a large amount to engage in alliance centralized procurement, the manufacturers will pay attention to it
    .
    " This is the reason for the centralized procurement of the above-mentioned province alliance
    .
    According to the rules, winning the bid exclusively is equivalent to "small country procurement" for many companies
    .
    The varieties are basically large varieties of drugs used in the hospital market, and it is understandable that participating companies are fighting prices
    .
    Some manufacturers have already expanded their circulation, and now they have the opportunity to enter the hospital, they can report at the circulation price.
    It is really impossible to reduce it slightly
    .
    Originally, the companies selling in the target regional hospitals wanted to keep the hospital market even more, and they would lower the price at all costs, so it appeared: troxerutin injection was 0.
    13 yuan each, citicoline sodium 0.
    496 yuan, injection Lansoprazole is 1.
    07 yuan per bottle, and lipoic acid injection is 1.
    39 yuan per bottle.
    .
    .
    There is basically no room for a drop in the above prices
    .
    There are two main reasons: one is that in the centralized procurement of the province or the centralized procurement of the provincial alliance, the price reduction is the main scoring weight item, and at the same time, the centralized procurement stipulates that it is best to declare the price limit effectively
    .
    Some products have low price limits, and some products with high price limits result in relatively low prices because of corporate price competition
    .
    Therefore, there are more types of companies involved in the price war, and the hospital market should be taken down first.

    .
    The selected manufacturers are basically striving for production capacity and strength, and many of them have large-scale aqueous injection production capacity that ranks high in the country or even in Asia
    .


    The "Opinions on Promoting the Normalization and Institutionalization of Centralized and Volume Procurement of Drugs" issued by the General Office   of the State Council in public hospitals to normalize centralized procurement further clarifies the normalized mechanism for centralized procurement of drugs.
    The main highlights include: Drugs with large amounts and high purchase amounts are included in the scope of procurement, and gradually cover all kinds of clinically necessary and reliable drugs on the market in China, so that all drugs should be collected
    .
    Drugs that have passed (including deemed passed) generic drug quality and efficacy consistency evaluations are given priority to be included in the scope of procurement
    .
    If the qualified drugs reach a certain amount or amount, the centralized procurement will be initiated
    .
    The key conditions of the selection are the medical insurance catalog, clinical necessity, large amount of medication and high amount, thus forming a trigger mechanism for centralized procurement
    .
    Explore the combined collection of drugs with similar indications or functions and indications but with different generic names, paving the way for the inclusion of large varieties of biosimilar drugs, including proprietary Chinese medicines, into the collection
    .
    Promote the construction of regional and national alliance procurement mechanisms; state, province, and municipal level development
    .
    Compared with national procurement, the provincial procurement and alliance procurement rules are more complicated, but they will eventually become mature and unified
    .

      Where to go for the representative of generic drugs
    After centralized procurement, there is basically no room for the marketing team for the varieties with a particularly large price drop, and there is no problem of manufacturer competition within the hospital for mass procurement, and there is no need for medical representatives to maintain in-hospital
    .
    At the same time, most of the collected varieties are stock varieties and mature varieties on the market, which have been used by doctors for many years and do not require academic promotion
    .
    Therefore, it is inevitable that the clinical sales team of the selected varieties will be abolished
    .
    In individual centralized procurement, the varieties with good prices, because they are purchased in quantity, most of the profits flow into the manufacturer’s pockets, which are left to the sales team andActing Limited's profit
    .
    Companies that focus on the clinical sales of generic drugs under centralized procurementhave laid off their employees.
    Where should the medical professionals go? The author has a few suggestions: Academic clinical representativeshave a very good relationshipwith hospital doctors, and they have strong medical expertise and rich experience in promotion and sales.
    You can consider working in innovative drug companies
    .
    Because innovative drugs need to be promoted to doctors academically, there is a lot of work to be done in the hospital
    .
    After the centralized procurement, more pharmaceutical companies will invest in research and development, and more innovative drugs will be launched on the market, providing more opportunities for outstanding pharmaceutical representatives
    .
    Commercial clinical representatives may consider adjusting channels
    .
    Transform from clinical representative to OTC representative, third terminal representative, and commercial representative
    .
    The out-of-hospital market is also a vast world, transforming from "bubble" in the market in grade hospitals to "run" in the clinics and pharmacies
    .
    As long as you are willing to study and work hard, gold will shine everywhere
    .
    It is also a good choice for the general health field and the medical equipment sales service industry
    .
    Many people in the pharmaceutical industry don’t make medicine anymore, but instead use their own expertise to do genetic testing, traditional Chinese medicine education, medical cosmetology, special medical food, hospital software services, marketing management consulting training, and other health-related subdivisions and service industries.

    .
    During the industry transition period, the main thing is to persist
    .
    And the change of career may have to start again
    .
    The author firmly believes that after three to five years, the day when the current round of medical reform changes from reform and oscillation to adjustment and rise is when the pharmaceutical industry resumes rapid growth
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.